Amended Current Report Filing (8-k/a)
July 02 2018 - 4:49PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 2)
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report
(Date of earliest event reported): March 7, 2017
OncBioMune
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-52218
|
|
20-2590810
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer
Identification No.)
|
|
11441
Industriplex Blvd, Suite 190.
Baton
Rouge, LA
|
|
70809
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(225)
227-2384
Registrant’s
telephone number, including area code
Not
applicable.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
EXPLANATORY
NOTE
On
March 13, 2017, OncBioMune Pharmaceuticals, Inc. filed a Current Report on Form 8-K (as amended by Amendment No. 1 filed on March
31, 2017, the “Original Form 8-K”) to report, among other things, the completion of the acquisition of all of the
issued and outstanding
capital stock of Vitel Laboratorios, S.A. de C.V., a Mexican variable
stock corporation (“Vitel”)
from
its shareholders Manuel Cosme Odabachian
and Carlos Fernando Alaman Volnie
. This Amendment No. 2 to the Original Form 8-K amends and supplements Item 9.01 of the
Original Form 8-K to include the financial information described in Item 9.01 below which was not previously filed with the Original
Form 8-K. Except as stated in the Explanatory Note, no other information contained in the Original Form 8-K is changed.
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
|
|
(a)
|
Financial
Statements of Business Acquired
|
The
audited financial statements of Vitel contemplated by this Item are filed as Exhibit 99.1 to this Amendment No. 2 to Current Report
on Form 8-K and incorporated herein by reference.
|
|
(b)
|
Pro
Forma Financial Information
|
The
pro forma financial information contemplated by this Item is filed as Exhibit 99.2 to this Amendment No. 2 to Current Report on
Form 8-K and incorporated herein by reference.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
ONCBIOMUNE
PHARMACEUTICALS, INC.
|
|
|
|
|
|
Dated:
July 2, 2018
|
By:
|
/s/
Jonathan F. Head
|
|
|
|
Jonathan
F. Head,
|
|
|
|
Chief
Executive Officer
|